ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for the treatment of renal and inflammatory diseases with
high unmet medical needs, announces that Stephen C. Glover,
Co-Founder, Chairman, Chief Executive Officer, and President, will
provide a corporate update as an invited speaker at the BIO CEO
& Investor Conference to be held in New York February 26 – 27,
2024. Mr. Glover will discuss upcoming development milestones for
Cholesterol Efflux MediatorTM VAR 200, for which a Phase 2a
clinical trial in patients with diabetic kidney disease is planned
to begin this quarter, and for Inflammasome ASC Inhibitor IC 100,
which is nearing completion of its preclinical program.
To learn more about ZyVersa and its robust development pipeline,
please schedule a one-on-one meeting with Mr. Glover through the
BIO conference portal.
Details regarding Mr. Glover’s presentation are as follows:
|
|
Event: |
BIO CEO & Investor Conference |
Date: |
Monday, February 26, 2024 |
Time: |
10:30 AM EST |
Location: |
The New York Marriott Marquis, Royale Room |
|
|
“We look forward to meeting with you at the BIO CEO &
Investor Conference to discuss the development status of ZyVersa’s
Cholesterol Efflux Mediator™ VAR 200, designed to ameliorate renal
lipid accumulation that damages the kidneys' filtration system in
renal patients, and Inflammasome ASC Inhibitor IC 100, designed to
attenuate initiation and perpetuation of inflammation that is
pathogenic in numerous inflammatory diseases, such as
atherosclerosis, Alzheimer’s and Parkinson’s diseases,” said Mr.
Glover.
About Cholesterol Efflux
MediatorTM VAR 200
VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase
2a-ready drug in development to ameliorate renal lipid accumulation
that damages the kidneys’ filtration system, leading to kidney
disease and its progression. VAR 200 passively and actively removes
excess lipids from the kidney.
Preclinical studies in animal models of diabetic kidney disease,
FSGS, and Alport syndrome demonstrate that removal of excess
cholesterol and lipids from the kidney’s filtration system with VAR
200 protects against structural damage and reduces excretion of
protein in the urine (proteinuria). VAR 200 has potential to treat
multiple kidney diseases, including diabetic kidney disease, and
rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and
Alport syndrome. For more information about VAR 200, Click
Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP3, and AIM2, to address inflammatory diseases in which multiple
inflammasome pathways are activated. Intracellularly, IC 100 binds
to ASC monomers, inhibiting inflammasome formation, thereby
blocking activation of IL-1β early in the inflammatory cascade. IC
100 also binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
spread and perpetuation of the inflammatory response that is
pathogenic in inflammatory diseases. Because active cytokines
amplify adaptive immunity through various mechanisms, IC 100, by
attenuating cytokine activation, also attenuates the adaptive
immune response. To review a white paper summarizing the mechanism
of action and preclinical data for IC 100, Click Here.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
peripheral inflammatory diseases. For more information, please
visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate, Media, and IR Contact:Karen
CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Set 2023 a Set 2024